| Literature DB >> 36078502 |
Lukasz Magnuszewski1,2,3, Aleksandra Wojszel4, Agnieszka Kasiukiewicz1,2, Zyta Beata Wojszel1,2.
Abstract
It is only by knowing the most common causes of falls in the hospital that appropriate and targeted fall prevention measures can be implemented. This study aimed to assess the frequency of falls in a hospital geriatrics ward and the circumstances in which they occurred and evaluate the parameters of the comprehensive geriatric assessment (CGA) correlating with falls. We considered medical, functional, and nutritional factors associated with falls and built multivariable logistic regression analysis models. A total of 416 (median age 82 (IQR 77-86) years, 77.4% women) hospitalizations in the geriatrics ward were analyzed within 8 months. We compared the results of a CGA (including health, psycho-physical abilities, nutritional status, risk of falls, frailty syndrome, etc.) in patients who fell and did not fall. Fourteen falls (3.3% of patients) were registered; the rate was 4.4 falls per 1000 patient days. They most often occurred in the patient's room while changing position. Falls happened more frequently among people who were more disabled, had multimorbidity, were taking more medications (certain classes of drugs in particular), had Parkinson's disease and diabetes, reported falls in the last year, and were diagnosed with orthostatic hypotension. Logistic regression determined the significant independent association between in-hospital falls and a history of falls in the previous 12 months, orthostatic hypotension, Parkinson's disease, and taking statins, benzodiazepines, and insulin. Analysis of the registered falls that occurred in the hospital ward allowed for an analysis of the circumstances in which they occurred and helped to identify people at high risk of falling in a hospital, which can guide appropriate intervention and act as an indicator of good hospital care.Entities:
Keywords: fall detection; fall prevention; fall risk factors; geriatric patients; in-patient fall
Mesh:
Year: 2022 PMID: 36078502 PMCID: PMC9518316 DOI: 10.3390/ijerph191710789
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Circumstances of falls (location, activity, and injury).
Figure 2Basic parameters examined immediately after the fall.
Characteristics of study participants—sociodemographic and medical correlates of falls.
| Characteristic | All | In-Patient | In-Patient | Missing Values | |
|---|---|---|---|---|---|
| No. (%) of patients | 416 (100.0) | 402 (96.7) | 14 (3.3) | - | - |
| Age (y), Md (IQR) | 82 (77.0–86.0) | 82 (77.0–86.0) | 81 (76.0–86.0) | 0.78 | - |
| Age (75+), | 350 (84.1) | 337 (83.8) | 13 (92.9) | 0.32 | - |
| Sex (men), | 94 (22.6) | 88 (21.9) | 6 (42.9) | 0.07 | - |
| Residence (rural), | 87 (20.9) | 85 (21.1) | 2 (14.3) | 0.41 | - |
| Length of hospital stay, days, Md (IQR) | 8 (5.0–9.0) | 8 (5.0–9.0) | 13 (8.8–17) |
| - |
| Number of chronic diseases b, Md (IQR) | 5.0 (3.0–6.0) | 5.0 (3.0–6.0) | 6.5 (5.0–8.0) |
| - |
| Multimorbidity, | 239 (57.5) | 226 (56.2) | 13 (92.9) |
| - |
| Falls in the last 12 months, | 157 (43.9) | 147 (42.4) | 10 (90.9) |
| 58 |
| Hospitalization in the last 12 months, | 122 (29.5) | 116 (29.0) | 6 (42.9) | 0.20 | 3 |
| Parkinson’s disease, | 55 (13.2) | 50 (12.4) | 5 (35.7) | 0.01 | - |
| Dementia, | 133 (32.0) | 127 (31.6) | 6 (42.9) | 0.27 | - |
| Depression, | 181 (56.9) | 172 (56.2) | 9 (75.0) | 0.12 | 98 |
| Diabetes, | 126 (30.3) | 116 (28.9) | 10 (71.4) | 0.001 | - |
| Hypertension, | 327 (78.6) | 315 (78.4) | 12 (85.7) | 0.39 | - |
| Orthostatic hypotension, | 57 (16.2) | 51 (15.0) | 6 (42.9) |
| 63 |
| Ischemic heart diseases, | 223 (53.6) | 213 (53.0) | 10 (71.4) | 0.13 | - |
| Osteoporosis, | 74 (17.8) | 73 (18.2) | 1 (7.1) | 0.25 | - |
| Osteoarthritis, | 324 (77.9) | 313 (77.9) | 11 (78.6) | 0.62 | - |
| Chronic cardiac failure, | 378 (90.9) | 364 (90.6) | 14 (100.0) | 0.22 | - |
| Atrial fibrillation, | 98 (23.6) | 95 (23.6) | 3 (21.4) | 0.57 | - |
| Peripheral arterial disease, | 64 (15.4) | 61 (15.2) | 3 (21.4) | 0.36 | - |
| Stroke/ TIA, | 56 (13.5) | 53 (13.18) | 3 (21.4) | 0.28 | - |
| Rheumatoid arthritis, | 20 (4.81) | 20 (5.0) | 0 (0.0) | 0.39 | - |
| Cholesterol- total, mg/dL, Md (IQR) | 178 (146.0–212.0) | 179 (147.0–213.0) | 133.5 (112.0–165.0) |
| 27 |
| LDL, mg/dL, Md (IQR) | 118 (87.0–143.0) | 120 (88.0–144.5) | 76.0 (67.0–87.0) |
| 118 |
| HDL, mg/dL, Md (IQR) | 48 (39.0–57.0) | 49 (40.0–58.0) | 40.5 (32.0–42.0) |
| 101 |
| Creatinin, mg/dL Md (IQR) | 0.98 (0.84–1.19) | 0.97 (0.84–1.18) | 1.3 (0.9–1.41) |
| 11 |
| eGFR, mL/min/1.73 m2, M (SD) | 57.9 (46.0–71.6) | 58.1 (46.1–71.9) | 49.4 (40.5–66.6) | 0.13 | 11 |
| TSH, mU/L, Md (IQR) | 1.4 (0.82–2.1) | 1.4 (0.82–2.1) | 1.8 (1.2–2.3) | 0.24 | 35 |
| Vitamin B12, pg/mL, Md (IQR) | 334.5 (242.6–430.6) | 336.2 (242.8–430.6) | 299.7 (221.8–343.8) | 0.46 | 38 |
| Na, mmol/L, Md (IQR) | 140.0 (138.0–141.0) | 140.0 (138.0–141.0) | 142.0 (134.0–142.0) | 0.60 | 10 |
| Ca, mmol/L, Md (IQR) | 4.6 (4.4–4.7) | 4.6 (4.4–4.7) | 4.5 (4.3–4.6) | 0.17 | 102 |
| Hemoglobin, g/dL, Md (IQR) | 12.6 (11.5–13.7) | 12.6 (11.5–13.7) | 12.6 (11.3–13.2) | 0.70 | 12 |
| Albumin ≥ 35 mg/mL, | 58 (14.9) | 54 (14.4) | 4 (28.6) | 0.14 | 27 |
| Systolic BP at admittance, mmHg, Md (IQR) | 130.0 (120.0–140.0) | 130.0 (120.0–140.0) | 131.0 (120–140.0) | 0.84 | 7 |
| Diastolic BP at admittance, mmHg, Md (IQR) | 70.0 (60.0–80.0) | 70.0 (60.0–80.0) | 70.0 (60.0–80.0) | 0.41 | 7 |
| CHA2DS2-VASc, Md (IQR) | 4.0 (3.0–5.0) | 4.0 (3.0–5.0) | 5.5 (4.0–6.0) |
| 2 |
a x2 test or Fisher’s exact test, as appropriate, for categorical variables; Mann–Whitney test for continuous or interval variables. In all analyses a two-tailed p-value of less than 0.05 was regarded as significant (significant differences are in bold). b of 15 chronic diseases (hypertension, ischemic heart disease, chronic cardiac failure, peripheral arterial disease, myocardial infarction, atrial fibrillation, history of transient ischemic attack (TIA) or stroke, diabetes or prediabetes, chronic renal disease, chronic obstructive pulmonary disease, dementia, parkinsonism, neoplasm, chronic osteoarthritis, and osteoporosis); BP—blood pressure; Ca—serum calcium; eGFR—glomerular filtration rate; HDL—high-density lipoprotein; IQR—interquartile range; LDL—low-density lipoprotein; Md—median value; n—number of cases; Na—serum sodium; TIA—transient ischemic attack; TSH—thyroid-stimulating hormone.
Characteristics of study participants—pharmacotherapy correlates of falls.
| Parameter | All | In-Patient | In-Patient | Missing Values | |
|---|---|---|---|---|---|
| No. (%) of patients | 416 (100.0) | 402 (96.7) | 14 (3.3) | - | - |
| Number of drugs at admittance, Md (IQR) | 6.0 (5.0–9.0) | 7.0 (5.0–9.0) | 10.5 (6.0–12.0) |
| 9 |
| Polypharmacy, | 322 (79.1) | 309 (78.6) | 13 (92.9) | 0.17 | 9 |
| α1-blockers, | 25 (6.1) | 23 (5.9) | 2 (14.3) | 0.19 | 10 |
| ß-blockers, | 258 (63.6) | 250 (63.8) | 8 (57.1) | 0.40 | 10 |
| Calcium channel blockers, | 144 (28.1) | 110 (28.1) | 4 (28.6) | 0.58 | 10 |
| ACEI/ ARB, | 222 (54.3) | 212 (53.7) | 10 (71.4) | 0.18 | 7 |
| Thiazide/ loop diuretics, | 196 (42.3) | 188 (48.0) | 8 (57.1) | 0.34 | 10 |
| Aldosterone- receptor antagonists (spironolactone, eplerenone), | 71 (17.5) | 66 (16.8) | 5 (35.7) | 0.07 | 10 |
| Statins, | 142 (35.0) | 133 (33.4) | 9 (64.3) |
| 10 |
| Digoxin, | 30 (7.4) | 28 (7.1) | 2 (14.3) | 0.27 | 10 |
| Antiarrhythmics, | 9 (2.2) | 9 (2.3) | 0 (0.0) | 0.56 | 10 |
| Insulin, | 31 (7.6) | 26 (6.6) | 5 (35.7) |
| 10 |
| Metformin, | 65 (16.0) | 58 (14.8) | 7 (50.0) |
| 10 |
| Oral anti-diabetic drugs (SM, metformin), | 90 (22.2) | 82 (20.1) | 8 (57.1) |
| 10 |
| Anti-diabetic drugs (SM, metformin, insulin), | 105 (25.9) | 96 (24.5) | 9 (64.3) |
| 10 |
| Thyroid hormones, | 30 (7.4) | 28 (7.1) | 2 (14.3) | 0.28 | 10 |
| Cholecalciferol, | 88 (21.7) | 86 (22.0) | 2 (14.3) | 0.49 | 10 |
| BDA, | 45 (11.1) | 41 (10.4) | 4 (28.6) | 0.03 | 9 |
| SSRI, | 115 (28.3) | 108 (27.5) | 7 (50.0) | 0.07 | 10 |
| Antidepressants (SSRI, mianserin), | 133 (32.8) | 126 (32.1) | 7 (50.0) | 0.13 | 10 |
| Quetiapine, | 49 (12.0) | 45 (11.5) | 4 (28.6) | 0.05 | 10 |
| Neuroleptics (quetiapine, haloperidol), | 54 (13.3) | 50 (12.8) | 4 (28.6) | 0.08 | 10 |
| AChE-I (donepezil, rivastigmine), | 41 (10.10) | 38 (9.7) | 3 (21.4) | 0.15 | 10 |
| Procognitive medications (AChEIs, memantine), | 46 (11.3) | 43 (11.0) | 3 (21.4) | 0.20 | 10 |
a x2 test or Fisher’s exact test, as appropriate, for categorical variables; Mann–Whitney test for continuous or interval variables. In all analyses, a two-tailed p-value of less than 0.05 was regarded as significant (significant differences are in bold). ACE-Is—angiotensin-converting enzyme inhibitors; AChE-I—acetylcholinesterase inhibitor; ARB—angiotensin receptor blocker; BDA—benzodiazepine; IQR—interquartile range; Md—median value; n—number of cases; SM—sulphonylureas; SSRI—selective serotonin reuptake inhibitor.
Characteristics of study participants—mental and physical abilities and nutritional correlates of falls.
| Characteristic | All | In-Patient | In-Patient | Missing Values | |
|---|---|---|---|---|---|
| No. (%) of patients | 416 (100.0) | 402 (96.7) | 14 (3.3) | - | - |
| AMTS, Md (IQR) | 8.0 (6.0–9.0) | 8.0 (6.0–9.0) | 7.0 (6.0–8.0) | 0.32 | 35 |
| MMSE, Md (IQR) | 21.0 (16.0–24.0) | 21.0 (16.0–25.0) | 19.0 (16.5–21.5) | 0.40 | 231 |
| GDS, Md (IQR) | 7.0 (3.0–10.0) | 6.5 (4.0–10.0) | 8.5 (3.0–11.0) | 0.36 | 52 |
| POMA, Md (IQR) | 23.0 (17.0–28.0) | 23.0 (18.0–28.0) | 17.0 (14.0–23.5) |
| 94 |
| POMA < 26, | 199 (61.8) | 188 (60.7) | 11 (91.7) |
| 94 |
| POMA < 19, | 95 (29.5) | 88 (28.4) | 7 (58.3) |
| 94 |
| TUG, s, Md (IQR) | 17.4 (11.9–28.0) | 17.2 (11.7–27.7) | 25.3 (20.7–29.1) | 0.11 | 115 |
| Gait speed, m/s, Md (IQR) | 0.65 (0.4–0.96) | 0.66 (0.4–0.59) | 0.43 (0.32–0.63) | 0.10 | 102 |
| Gait speed ≤ 0.8 m/s, | 166 (52.9) | 158 (52.0) | 8.0 (80.0) | 0.08 | 102 |
| Handgrip strength, kg, Md (IQR) | 18.2 (13.7–22.8) | 18.1 (13.8–22.8) | 19.4 (13.2–22.5) | 0.92 | 66 |
| Dynapenia, | 233.0 (66.6) | 223.0 (66.2) | 10.0 (76.9) | 0.32 | 66 |
| Norton scale, Md (IQR) | 17.0 (15.0–19.0) | 17.0 (15.0–19.0) | 16.0 (15.0–18.0) | 0.25 | 6 |
| Clinical Frailty Scale, Md (IQR) | 5.0 (4.0–5.0) | 5.0 (4.0–5.0) | 5.5 (5.0–6.0) |
| - |
| Clinical Frailty Scale classification | 0.06 | - | |||
| Robust, | 62 (14.9) | 62 (15.4) | 0 (0) | ||
| Pre-frail, | 124 (29.8) | 122 (30.3) | 2 (14.3) | ||
| Frail, | 230 (55.3) | 218 (54.2) | 12 (85.7) | ||
| Severe frailty (CFS = 6 or 7), | 102 (24.5) | 95 (23.6) | 7 (50.0) |
| - |
| MNA-SF, Md (IQR) | 12.0 (9.0–13.0) | 12.0 (9.0–13.0) | 12.0 (7.0–13.0) | 0.54 | 12 |
| MNA-SF score < 8, | 198 (49.0) | 192 (49.2) | 6 (42.9) | 0.42 | 12 |
| BMI, kg/m2, M (SD) | 28.5 (25.0–33.6) | 28.5 (24.9–33.7) | 30.3 (27.0–31.6) | 0.55 | 62 |
| BMI < 24 kg/m2, | 66 (18.6) | 65 (19.0) | 1 (8.3) | 0.31 | 62 |
| BMI > 30 kg/m2, | 148 (41.8) | 141 (41.2) | 7 (58.3) | 0.18 | 62 |
| WHR, Md (IQR) | 0.90 (0.87–0.95) | 0.90 (0.87–0.96) | 0.93 (0.87–0.96) | 0.45 | 63 |
| MAC, cm, Md (IQR) | 28.0 (26.0–30.0) | 28.0 (26.0–30.0) | 28.5 (26.0–30.0) | 0.70 | 49 |
| MAC ≤ 22 cm, | 89 (24.3) | 87 (24.7) | 2 (14.3) | 0.29 | 49 |
| CC, cm, Md (IQR) | 34.0 (31.5–37.0) | 34.0 (31.0–37.0) | 35.5 (33.0–40.0) | 0.12 | 51 |
| CC < 31 cm, | 74 (20.3) | 72 (20.5) | 2 (14.3) | 0.43 | 51 |
a x2 test or Fisher’s exact test, as appropriate, for categorical variables; Mann–Whitney test for continuous or interval variables. In all analyses, a two-tailed p-value of less than 0.05 was regarded as significant (significant differences are in bold). AMTS—Abbreviated Mental Test Score; BMI—body mass index; CC—calf circumference; CFS—7-point Clinical Frailty Scale; IQR—interquartile range; Md—median value; MAC—mid arm circumference; MMSE—Mini Mental State Examination; MNA-SF—Mini Nutritional Assessment Short Form; n—number of cases; POMA—Performance Oriented Mobility Assessment; TUG—Timed Up-and-Go test.
Characteristics of study participants—ADL and IADL correlates of falls.
| Characteristic | All | In-Patient | In-Patient | Missing Values | |
|---|---|---|---|---|---|
| Barthel Index, Md (IQR) | 90.0 (70.0–100.0) | 90.0 (70.0–100.0) | 77.5 (55.0–85.0) | 0.06 | 6 |
| Independent in: | |||||
| Bowel control, | 360 (87.4) | 346 (86.9) | 14 (100.0) | 0.15 | 4 |
| Feeding, | 343 (83.0) | 332 (83.2) | 11 (78.6) | 0.65 | 3 |
| Grooming, | 333 (80.6) | 332 (80.7) | 11 (78.6) | 0.84 | 3 |
| Transferring (bed to chair and back), | 297 (72.1) | 289 (72.6) | 8 (57.1) | 0.20 | 4 |
| Mobility on level surfaces, | 292 (70.4) | 284 (70.8) | 8 (57.1) | 0.27 | 1 |
| Toilet use, | 280 (67.8) | 276 (69.2) | 4 (28.6) |
| 3 |
| Dressing, | 276 (66.8) | 270 (67.7) | 6 (42.9) | 0.05 | 3 |
| Stairs managing, | 227 (55.2) | 219 (55.2) | 8 (57.1) | 0.88 | 5 |
| Bladder control, | 218 (53.0) | 214 (53.9) | 4 (28.6) | 0.05 | 5 |
| Bathing, | 209 (21.4) | 206 (51.9) | 3 (21.4) |
| 5 |
| IADL, Md (IQR) | 7.0 (3.0–11.0) | 7.0 (3.0–11.0) | 4.5 (2.0–8.0) | 0.07 | 10 |
| Independent in: | |||||
| Phone talk, | 273 (66.8) | 267 (67.6) | 6 (42.9) | 0.05 | 7 |
| Taking medicines, | 235 (57.5) | 229 (58.0) | 6 (42.9) | 0.26 | 7 |
| Disposing of money, | 230 (56.4) | 226 (57.4) | 4 (28.6) |
| 9 |
| Making meals, | 177 (43.7) | 174 (44.5) | 3 (21.4) | 0.07 | 11 |
| Going shopping, | 126 (31.1) | 125 (32.0) | 1 (7.1) |
| 11 |
| Doing housework, | 101 (25.0) | 101 (25.8) | 0 (0.0) |
| 11 |
a x2 test or Fisher’s exact test, as appropriate, for categorical variables; Mann–Whitney test for continuous or interval variables. In all analyses, a two-tailed p-value of less than 0.05 was regarded as significant (significant differences are in bold). ADL—activities of daily living; IADL—instrumental activities of daily living (DUKE OARS—Older Americans Resources and Services Program); IQR—interquartile range; Md—median value; n—number of cases.
Predictors of falls—backward multivariable logistic regression models.
| Model 1 | Model 2 | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Falls in the last 12 months | 10.89 | 1.28–92.56 | 0.03 | 50.92 | 1.84–1412.6 | 0.02 |
| Orthostatic hypotension | 4.76 | 1.13–19.97 | 0.03 | 14.53 | 1.12–189.27 | 0.04 |
| CFS | 2.63 | 1.08–6.42 | 0.03 | 2.84 | 0.96–8.47 | 0.06 |
| Parkinson’s disease | 37.64 | 2.71–522.02 | 0.007 | |||
| Statins | 20.91 | 1.23–355.31 | 0.04 | |||
| Insulin | 56.79 | 3.66–880.59 | 0.004 | |||
| Benzodiazepines | 31.11 | 2.41–540.72 | 0.009 | |||
| Negelkerk’s R2 | 0.208 | 0.579 | ||||
| % correctly predicted | 96.7% | 98.2% | ||||
| sensitivity | 0% | 44.4% | ||||
| specificity | 100% | 100% | ||||
| Hosmer–Lemeshow goodness of fit | 0.877 | 0.939 | ||||
|
|
| |||||
| Variables in block 1 and block 2 | Falls in the last 12 months, orthostatic hypotension, POMA, CFS | Barthel index, IADL, sex, DM, Parkinson’s disease, number of diseases, statins, insulin, SM, metformin, quetiapine, neuroleptics, BDA, SSRI, cholesterol, creatinine | ||||
BDA—benzodiazepines; CFS—Clinical Frailty Scale; CI—confidence interval; DM—diabetes mellitus; IADL—instrumental activities of daily living; OR—odds ratio; POMA—Performance Oriented Mobility Assessment; SM—sulfonylureas; SSRI—selective serotonin reuptake inhibitor.
Predictors of falls—the final multivariable logistic regression model (enter method).
| Model 3 | |||
|---|---|---|---|
| OR | 95% CI | ||
| Falls in the last 12 months | 41.74 | 2.47–705.95 | 0.010 |
| Orthostatic hypotension | 21.53 | 2.25–206.28 | 0.008 |
| Parkinson’s disease | 40.89 | 3.28–510.16 | 0.004 |
| Statins | 43.96 | 2.97–651.72 | 0.006 |
| Insulin | 34.76 | 3.33–362.75 | 0.003 |
| Benzodiazepines | 34.93 | 2.82–432.16 | 0.006 |
| Negelkerk’s R2 | 0.541 | ||
| % correctly predicted | 97.5% | ||
| sensitivity | 27.3% | ||
| specificity | 100% | ||
| Hosmer–Lemeshow goodness of fit | 0.703 |
CI—confidence interval; OR—odds ratio.